Evidence map›Paper›PMID 42554036›Full record

ArticleEchocardiography (Mount Kisco, N.Y.)2026

TrueVue Plus Light and Glass Three-Dimensional Echocardiography for Heart Diseases: A Revolution in Cardiovascular Imaging.

Ran Qu, Xueying Tan, Yixin Chen, Sihua Ren, Aijiao Sun, Yangjie Xiao, Wei Qiao, Yanxiao Liang, Yilong Pan, Yunmeng Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Echocardiography (Mount Kisco, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ran QuDepartment of Echocardiography, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xueying TanDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China.
Yixin ChenDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China.
Sihua RenPostgraduate Work Department, The First Hospital of China Medical University, Shenyang, China.
Aijiao SunDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China.
Yangjie XiaoDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China.
Wei QiaoDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China.
Yanxiao LiangDepartment of Cardiac Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Yilong PanDepartment of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China.
Yunmeng ZhangDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China.
Liping HuangDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China.
Feifei SunDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China.

Funding

345 Talent Project of Shengjing Hospital M0282Young Scientists Fund of the National Natural Science Foundation of China 81901763
6 · The paper itself

Abstract

purposeTo explore the value and operational points of TrueVue, TrueVue Light, and TrueVue Glass, which are emerging, advanced three-dimensional echocardiographic (3DE) technologies, for the clinical diagnosis of heart diseases.

methodsEchocardiography examinations were performed in 272 patients with suspected structural heart diseases. Two-dimensional (2D) and real-time 3DE methods, including traditional and new 3D imaging techniques were used. The Likert scale was used to compare the novel and traditional techniques. The operational capabilities, advantages, and limitations of the new techniques were assessed.

resultsTwenty-one (7.7%) patients had normal cardiac structure, 98 (36.0%) had congenital heart diseases, 70 (25.7%) had acquired valvular diseases, 43 (15.8%) had cardiomyopathy, and 40 (14.7%) had other cardiac structural abnormalities. TrueVue provided high-resolution, realistic 3D images. TrueVue Light provided a virtual light source to apply light and shade effects that could be set at different locations and depths. TrueVue Glass was used for highlighting the borders of the chambers, thin valves, and vessels. The evaluation scores (Likert scale) of the novel 3DE tools were higher than those of traditional 3DE systems (p < 0.0001).

conclusionsFor viewing various cardiac lesions, novel 3DE imaging was preferred over conventional displays in all surveyed groups. The use of TrueVue, TrueVue Light, and TrueVue Glass 3DE provides effective reference information, increases the diagnostic accuracy and efficiency, and optimizes the workflow of doctors who diagnose and treat heart diseases.

Indexed as

Echocardiography, Three-DimensionalHeart DiseasesImage EnhancementAdolescentAdultChildEquipment DesignFemaleHumansMaleMiddle AgedReproducibility of ResultsSensitivity and Specificitycardiac imaging techniquesechocardiographyheart diseaseTrueVue

Identifiers

PMID42554036
PMCPMC13439488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.